These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 22116003)

  • 21. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.
    Price MJ; Murray SS; Angiolillo DJ; Lillie E; Smith EN; Tisch RL; Schork NJ; Teirstein PS; Topol EJ;
    J Am Coll Cardiol; 2012 May; 59(22):1928-37. PubMed ID: 22624833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
    Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.
    Frere C; Cuisset T; Morange PE; Quilici J; Camoin-Jau L; Saut N; Faille D; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
    Am J Cardiol; 2008 Apr; 101(8):1088-93. PubMed ID: 18394438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
    Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
    Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
    Tantry US; Bliden KP; Wei C; Storey RF; Armstrong M; Butler K; Gurbel PA
    Circ Cardiovasc Genet; 2010 Dec; 3(6):556-66. PubMed ID: 21079055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
    Bouman HJ; Harmsze AM; van Werkum JW; Breet NJ; Bergmeijer TO; Ten Cate H; Hackeng CM; Deneer VH; Ten Berg JM
    Heart; 2011 Aug; 97(15):1239-44. PubMed ID: 21628721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.
    Hwang SJ; Jeong YH; Kim IS; Koh JS; Kang MK; Park Y; Kwak CH; Hwang JY
    Thromb Res; 2011 Jan; 127(1):23-8. PubMed ID: 21075428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
    Hochholzer W; Trenk D; Fromm MF; Valina CM; Stratz C; Bestehorn HP; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2010 Jun; 55(22):2427-34. PubMed ID: 20510210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
    Ono T; Kaikita K; Hokimoto S; Iwashita S; Yamamoto K; Miyazaki Y; Horio E; Sato K; Tsujita K; Abe T; Deguchi M; Tayama S; Sumida H; Sugiyama S; Yamabe H; Nakamura S; Nakagawa K; Ogawa H
    Thromb Res; 2011 Dec; 128(6):e130-6. PubMed ID: 21862109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble P-selectin level correlates with acetylsalicylic acid but not with clopidogrel response in patients with stable coronary artery disease after a percutaneous coronary intervention.
    Kaufmann J; Wellnhofer E; Kappert K; Urban D; Meyborg H; Hauptmann T; Müller A; Meixner M; Graf K; Fleck E; Stawowy P
    Coron Artery Dis; 2013 Jun; 24(4):312-20. PubMed ID: 23549485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.
    Bonello-Palot N; Armero S; Paganelli F; Mancini J; De Labriolle A; Bonello C; Lévy N; Maillard L; Barragan P; Dignat-George F; Camoin-Jau L; Bonello L
    Am J Cardiol; 2009 Dec; 104(11):1511-5. PubMed ID: 19932784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention.
    Rideg O; Komócsi A; Magyarlaki T; Tokés-Füzesi M; Miseta A; Kovács GL; Aradi D
    Pharmacogenomics; 2011 Sep; 12(9):1269-80. PubMed ID: 21806387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
    Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
    JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.
    Zou JJ; Xie HG; Chen SL; Tan J; Lin L; Zhao YY; Xu HM; Lin S; Zhang J; Wang GJ
    Eur J Clin Pharmacol; 2013 Apr; 69(4):771-7. PubMed ID: 23001453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Modified Impedance Whole Blood Platelet Aggregation Method Detecting Platelet Function in ACS Patients with Different CYP2C19 Genotypes.
    Cui C; Qiao R; Zhang J
    Clin Lab; 2016; 62(1-2):13-20. PubMed ID: 27012029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
    Arima Y; Hokimoto S; Akasaka T; Mizobe K; Kaikita K; Oniki K; Nakagawa K; Ogawa H
    J Cardiol; 2015 Jun; 65(6):494-500. PubMed ID: 25156215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
    Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
    Mega JL; Hochholzer W; Frelinger AL; Kluk MJ; Angiolillo DJ; Kereiakes DJ; Isserman S; Rogers WJ; Ruff CT; Contant C; Pencina MJ; Scirica BM; Longtine JA; Michelson AD; Sabatine MS
    JAMA; 2011 Nov; 306(20):2221-8. PubMed ID: 22088980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.